IceCure Medical(NASDAQ:ICCM) reported declining revenue and gross profit for the six months ended June 30, 2025, compared to 2024, citing a shipment delay of over $200,000 originally scheduled for Q2 ...
This article first appeared on GuruFocus. Icecure Medical Ltd (NASDAQ:ICCM) is set to release its Q4 2025 earnings on Mar 17, 2026. The consensus estimate for Q4 2025 revenue is $1.90 million, and the ...
Revenue-- Revenue (GAAP) totaled approximately $1.25 million for the six months ended June 30, 2025, down from $1.75 million in 2024, including over $200,000 in shipments delayed in Q2 2025 due to the ...
Michael Polyviou: Thank you, Hilla, and welcome to IceCure Medical Ltd's conference call to review the financial results as of and for the twelve months ended December 31, 2025, and provide an update ...
Good morning, and thank you for standing by. Currently, all the participants are in a listen-only mode. After management’s discussion, there will be a question-and-answer session. Please be advised ...
Ladies and gentlemen, thank you for standing by. Good morning, and thank you for standing by. [Operator Instructions] Please be advised that today's conference call is being recorded. I would now like ...
IceCure Medical(NASDAQ:ICCM)'s recent FDA clearance for ProSense in breast cancer catalyzed new national guidelines, expanded reimbursement coverage, and increased U.S. and international commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results